Most accessed

  • Published in last 1 year
  • In last 2 years
  • In last 3 years
  • All

Please wait a minute...
  • Select all
    |
  • ZHANG Ming-fa, SHEN Ya-qin
    KANGGANRAN YAOXUE. 2025, 22(12): 1187-1195. https://doi.org/10.13493/j.issn.1672-7878.2025.12-001
    Berberine is a widely used bioactive compound with diverse pharmacological effects, including anti-inflammation, antioxidation, cytoprotection, broad-spectrum antibacterial and antiviral activities, as well as antitumor, antidiarrheal, antiarrhythmic, antihypertensive, hypoglycemic and lipid-regulating functions. Its pharmacological activities involve multiple systems and metabolic fields such as the digestive system, central nervous system, cardiovascular system and respiratory system. Although berberine has been used clinically for more than 60 years, its officially approved oral indications in China are still limited to intestinal infections, which fails to fully reflect its extensive pharmacological potential. The authors have previously reviewed the research progress in cerebral protection, cognitive impairment, Parkinson's disease, depression, antitumor, antiviral and hypoglycemic effects of berberine. In this article, the clinical research progress in prevention and treatment of berberine against hyperglycemia is further reviewed, so as to provide a reference for clinicians, promote the expansion of its clinical applications and give full play to its potential therapeutic value.
  • ZHANG Yi-zhi, LI Jia, HUANG Zhan-qing, LU Fang-yi, CHEN Jie, WANG Bao-xiao
    KANGGANRAN YAOXUE. 2025, 22(12): 1237-1244. https://doi.org/10.13493/j.issn.1672-7878.2025.12-009
    Objective: To comprehensively assess the clinical comprehensive value of four domestically marketed neurokinin-1 (NK-1) receptor antagonists (Aprepitant Capsules, Aprepitant Injection, Fosaprepitant Dimeglumine for Injection, Netupitant and Palonosetron Hydrochloride Capsules) in preventing and treating chemotherapy-induced nausea and vomiting (CINV), so as to provide a reference for individualized patient therapy and drug selection in medical institutions. Methods: Based on the evaluation framework established in the Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions (2nd Edition), quantitative scoring and comprehensive evaluation were performed on the above drugs in terms of pharmaceutical properties, effectiveness, safety, economy, and other attributes. Results: All four NK-1 receptor antagonists achieved a comprehensive score above 70, meeting the criteria of ''strongly recommended'' or suggested to be retained in the guidelines. The scores ranked in descending order: Netupitant and Palonosetron Hydrochloride Capsules (78.40), Aprepitant Capsules (76.53), Aprepitant Injection (74.36), and Fosaprepitant Dimeglumine for Injection (73.38). Netupitant and Palonosetron Hydrochloride Capsules performed outstandingly in pharmaceutical properties and economy; Fosaprepitant Dimeglumine showed therapeutic advantages in acute-phase CINV control; Aprepitant Capsules had more sufficient evidence for pediatric use. Conclusion: The selection and evaluation based on the Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions (2nd Edition) can support drug selection in medical institutions and promote scientific, rational and safe medication. All four NK-1 receptor antagonists exhibit satisfactory clinical utility in preventing and treating CINV and are eligible for recommendation into drug supply catalogs.
  • KANGGANRAN YAOXUE. 2025, 22(12): 1250-1255. https://doi.org/10.13493/j.issn.1672-7878.2025.12-011
    目的: 探讨根本原因分析(root cause analysis,RCA)在医院门急诊药房调剂差错中的应用效果,提出针对性防范策略,为提升药房服务质量,保障患者用药安全提供参考。方法: 选取 2021 年 1 月—2022 年 12 月(整改前)和2023 年 1 月—2024 年 12 月(整改后)南阳市第一人民医院门急诊药房药品调剂差错数据作为研究资料,统计整改前药品调剂差错类型,采用 RCA 法分析其根本原因,调整药品管理措施,比较整改前后药品调剂差错率、类型分布、药师工作满意度和患者满意度。结果: 整改前收集调剂药品数据 4 510 例,出现调剂差错 115 例,调剂差错发生率为 2.55%(115/4 510),整改后收集调剂药品数据 5 638 例,出现调剂差错 86 例,调剂差错发生率为 1.53%(86/5 638),整改后调剂差错发生率明显低于整改前(χ2=13.547,P<0.001);整改后,名称相似、包装相似、用法用量错误是导致门急诊药房调剂差错的主要类型,发生率分别为 0.35%、0.28%、0.23%;整改后,药师对工作环境、工作流程、设备支持、职业认同感、心理支持满意度均高于整改前(P<0.05);患者对药品发放准确性、药师服务态度、等候时间、用药指导满意度均高于整改前(P<0.05)。结论: 应用 RCA 可有效识别门急诊药房调剂差错的系统性原因,通过实施针对性改进措施能显著降低差错发生率,优化药品管理流程,并同步提升药师与患者满意度,对促进用药安全具有重要实践价值。
  • WU Chang-ying, HE Cai-jing, LIANG Shuang, LIANG Shuai
    KANGGANRAN YAOXUE. 2025, 22(12): 1196-1201. https://doi.org/10.13493/j.issn.1672-7878.2025.12-002
    Objective: To analyze the anti-infective therapy and pharmaceutical care process of a patient with cerebral hemorrhage complicated by pulmonary infection, so as to provide a reference for the clinical diagnosis and treatment of such patients. Methods and Results: A 21-year-old male patient was admitted due to ''dizziness accompanied by recurrent convulsions for more than 8 hours''. Emergency cranial CT revealed cerebral hemorrhage in the right frontal lobe and left parietal lobe. The patient was given nasal feeding of a prescription for acute stroke stage (Banxia Baizhu Tianma Decoction combined with blood-activating and stasis-resolving traditional Chinese medicine) to dispel wind, resolve phlegm, activate blood and unblock collaterals, together with symptomatic treatments such as dehydration to reduce intracranial pressure and seizure control. ''Craniotomy with hematoma evacuation, decompressive craniectomy and tracheotomy'' were performed on day 2, and ''total cerebral angiography via the aortic arch'' on day 4 after admission. Postoperatively, the patient developed fever with a peak temperature of 39 ℃, and lung CT suggested infection. Empirical anti-infective therapy with ceftriaxone, antipyretic treatment and resuscitation with Suhexiang Pills were administered. On day 13 after admission, the patient still had persistent high fever (40.6 ℃) with elevated infection indicators, accompanied by flushed face, red tongue with yellow and greasy coating, wiry and rapid pulse, and excessive phlegm. Modified Zhengan Xifeng Decoction was added, and a clinical pharmacist of traditional Chinese medicine was consulted. The pharmacist recommended discontinuing Suhexiang Pills and switching to Angong Niuhuang Pills, and adjusting the anti-infective regimen to moxifloxacin combined with cefoperazone-sulbactam sodium, which was adopted by the physician. On day 14, the imaging manifestations of pulmonary infection deteriorated, accompanied by liver dysfunction (considered to be related to sodium valproate). The pharmacist suggested upgrading the anti-infective drug to meropenem, adjusting the antiepileptic regimen to levetiracetam combined with topiramate, switching traditional Chinese medicine to modified Qingying Decoction, and performing next-generation sequencing (NGS) of alveolar lavage fluid and blood, which was adopted by the physician. On day 16, NGS results indicated Ureaplasma urealyticum and human herpesvirus type 1, so doxycycline and acyclovir were added. After comprehensive intervention, infection indicators gradually improved, liver function recovered, and the patient was transferred back to his native place for rehabilitation after his condition stabilized. Conclusion: Cerebral hemorrhage complicated by pulmonary infection or even bloodstream infection is clinically complex. Etiological evidence should be obtained as early as possible on the basis of empirical anti-infective therapy. Individualized treatment with integrated traditional Chinese and Western medicine should be implemented combined with liver and kidney function and changes in individual syndromes. Synergistic management of syndrome-based Chinese medicine selection and Western medicine safety is essential to improve efficacy and ensure medication safety.
  • CHEN Shao-fang, HONG Hui-qi
    KANGGANRAN YAOXUE. 2025, 22(12): 1202-1208. https://doi.org/10.13493/j.issn.1672-7878.2025.12-003
    Objective: To analyze the anti-infective treatment and pharmaceutical care process of a patient with severe pneumonia complicated by empyema caused by Tropheryma whipplei, so as to provide a reference for the clinical treatment and safe and rational drug use of this rare infection. Methods and Results: A patient was admitted due to ''chest pain, hemoptysis and fever for half a day'', and diagnosed with severe pneumonia with left pleural effusion. After admission, the patient received empirical anti-infective therapy with piperacillin sodium-tazobactam sodium combined with moxifloxacin. During treatment, the patient presented persistent hypokalemia and prolonged QT interval(QTc 490 ms). Tropheryma whipplei (sequence number: 108) was detected by metagenomics next-generation sequencing (mNGS) of bronchoalveolar lavage fluid. Based on the etiological examination results and drug susceptibility characteristics, the clinical pharmacist recommended switching to doxycycline combined with meropenem. After left thoracentesis and drainage, the infection was well controlled. The clinical pharmacist suggested deescalation of antibacterial drugs to ceftriaxone plus doxycycline for sequential therapy. After nearly 4 weeks of hospitalization, the patient's clinical symptoms were significantly relieved, body temperature returned to normal, infection indicators decreased remarkably, and imaging showed absorption of pulmonary lesions. The patient was discharged with continued doxycycline treatment. Conclusion: Through participation in the individualized treatment process of a patient with Tropheryma whipplei pneumonia complicated by empyema, clinical pharmacists have implemented whole-process pharmaceutical care to help optimize the anti-infective regimen and ensure medication safety, reflecting their professional value in the multidisciplinary treatment of rare pathogen infections.
  • YAO Guo-jing, TANG Lin-lin, ZHANG Hai-xia
    KANGGANRAN YAOXUE. 2025, 22(12): 1215-1221. https://doi.org/10.13493/j.issn.1672-7878.2025.12-005
    Objective: To analyze one case of methotrexate (MTX)-induced liver injury, collect adverse events of MTX-induced liver injury from the FDA Adverse Event Reporting System (FAERS) database and analyze the onset time, so as to provide a reference for clinical individualized medication. Methods and Results: A 38-year-old female patient diagnosed with ectopic pregnancy received conservative treatment with MTX (87 mg, single deep intramuscular injection in both buttocks). On the 4th day after drug withdrawal, serum human chorionic gonadotropin (HCG) was 441 mIU/mL; on the 7th day after drug withdrawal, serum HCG was 426 mIU/mL, with only a 3% decrease compared with that on the 4th day after MTX treatment. Liver function test results showed alanine aminotransferase (ALT) 144 U/L and aspartate aminotransferase (AST) 102 U/L, suggesting drug-induced liver injury. The patient was given Glutathione for Injection and Monoammonium Glycyrrhizinate and Cysteine and Sodium Chloride Injection for liver protection, combined with surgical treatment. Laparoscopic salpingectomy of the affected side was performed on the 8th day after drug withdrawal. On the 11th day after drug withdrawal, liver function was improved (ALT 75 U/L, AST 54 U/L). On the 13th day after drug withdrawal, the patient was discharged with stable condition, continued to take diammonium glycyrrhizinate enteric-coated capsules for liver protection, and was scheduled for reexamination of liver function and serum HCG one week later. On the 22nd day after drug withdrawal, liver function test results showed ALT 46.9 U/L and negative serum HCG. Meanwhile, based on relevant data from the FAERS database, with indication limited to ectopic pregnancy and study period from 2004 to 2024, a total of 56 adverse events related to liver injury were screened. The system organ classes included hepatobiliary diseases and various examinations, and the preferred terms for liver function injury in examinations mainly included abnormal liver function test, elevated liver enzymes, elevated serum bilirubin, etc. The onset time of MTX-induced liver injury ranged from 2 days to 30 days. Conclusion: Clinical attention should be paid to MTX-induced liver dysfunction. Liver function test should be carried out as early as the 2nd day after medication, and the period within 30 days is the key monitoring window.
  • KANGGANRAN YAOXUE. 2025, 22(12): 1265-1270. https://doi.org/10.13493/j.issn.1672-7878.2025.12-013
    目的: 分析成人破伤风患者的临床特点与死亡的危险因素,为临床诊疗提供参考。方法: 选取 2017 年 1 月—2024 年 9 月郑州市第六人民医院收治的 126 例破伤风成人患者的临床资料作为研究对象,收集患者的一般资料、基础疾病、受伤部位、潜伏期、致伤因素、临床表现及其并发症、治疗和预后情况等,按预后情况将患者分为死亡组(n=37)与非死亡组(n=89),分析患者的临床特点,采用单因素、多因素 Logistic 回归分析成人破伤风患者死亡的危险因素。结果: 126 例成人破伤风患者的主要受伤部位为下肢(69 例,占 54.76%)、上肢(40 例,占 31.75%)和头部(7 例,占 5.56%),主要致伤因素为铁钉、铁丝、刀、犁、镰刀外伤(43 例,占 34.13%),树枝、草根、玻璃、竹制品外伤(35 例,占 27.78%),以及车祸、挤压伤、重物砸伤(33 例,占 26.19%),平均潜伏期为(9.31±2.54)d;发生全身性破伤风 107 例(占 84.92%)、局限性破伤风 19 例(占 15.08%),发生并发症 73 例(占 57.94%)、自主神经功能障碍 14 例(占 11.11%);患者 Ablett 分级为 Ⅰ、Ⅱ、Ⅲ、Ⅳ 级的分别为 23 例(占 18.25%)、26 例(占 20.63%)、64 例(占 50.79%)和 13 例(占 10.32%),Ablett 分级为 Ⅲ、Ⅳ 级的患者(77 例,占 61.11%)均入住 ICU;基础疾病为冠心病、高血压,潜伏期、抗毒素用量、急性生理学和慢性健康状况评价(acute physiology and chronic health evaluation,APACHE)Ⅱ 评分,并发喉痉挛致窒息、心律失常,以及自主神经功能障碍、Ablett 分级为患者死亡的相关因素(P<0.05);多因素 Logistic 回归分析结果显示,抗毒素用量、APACHE Ⅱ 评分,并发喉痉挛致窒息、心律失常,以及 Ablett 分级为 Ⅲ、Ⅳ 级是成人破伤风患者死亡的危险因素(P<0.05)。结论: 临床诊治成人破伤风患者需注重分析其临床特点,抗毒素用量、APACHE Ⅱ评分,并发喉痉挛致窒息、心律失常,以及 Ablett 分级为 Ⅲ、Ⅳ 级是成人破伤风患者死亡的危险因素,临床治疗时需给予重点关注。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1290-1296. https://doi.org/10.13493/j.issn.1672-7878.2025.12-018
    目的: 探讨药学科普干预对 2 型糖尿病(type 2 diabetes mellitus,T2DM)患者注射用降糖药认知度与治疗依从性的影响,为促进临床合理用药提供依据。方法: 选取 2024 年 4—12 月在苏州市市立医院就诊的 150 例 T2DM 患者作为研究对象,将其随机分为 2 组,每组 75 例;对照组患者接受医院药师提供的常规药学服务,观察组在对照组基础上接受结构化的药学科普干预方案,采用针对糖尿病患者用药依从性的调查问卷评估其用药依从性,采用自行设计的调查问卷评估患者对胰岛素和胰岛素类似物正确使用的知识掌握程度;测量并记录 2 组患者在干预前、干预后 3 个月和干预后 6 个月的空腹血糖值;采用参考糖尿病管理自我效能量表修订形成的调查问卷评估自我管理能力。结果: 150 例患者中,男性多于女性(92 例 vs 58 例);患者年龄为 42~71 岁,平均年龄为(57.46±7.67)岁;112 例(占 74.67%)患者与家人同住,38 例(占 25.33%)患者为独居状态;干预后,观察组患者的用药依从率显著高于对照组(90.67% vs 78.67%,P<0.001),患者的认知良好率高于对照组(92.00% vs 76.00%,P<0.05);干预后 3 个月和 6 个月,观察组患者的空腹血糖水平均低于对照组(P<0.05);干预后 6 个月,观察组患者的自我管理效能评分高于对照组(P<0.05)。结论: 对使用注射类降糖药的 2 型糖尿病患者实施结构化的药学科普干预,可有效提升其药物知识水平、治疗依从性与自我管理效能,并有助于实现更优的血糖控制;以患者教育为核心的药学干预是糖尿病综合管理中值得推广的重要环节。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1256-1264. https://doi.org/10.13493/j.issn.1672-7878.2025.12-012
    目的: 探究喘息性疾病患儿监护人居家雾化用药安全风险知信行(knowledge-attitude-practice,KAP)现状及其影响因素,为居家雾化安全用药科普干预内容、方法的设置和促进治疗的有效开展提供依据。方法: 采用方便抽样法,选取焦作、郑州、开封、周口、南阳、信阳、新乡等市 18 岁以下喘息性疾病患儿的主要监护人为研究对象,以“问卷星”平台和现场发放问卷的形式对居家雾化用药进行 KAP 情况调查,分析受访者的接受度、用药 KAP 现状及其风险点,并采用单因素方差分析、多重线性回归等方法分析其影响因素。结果: 共纳入问卷 666 份,接受居家雾化吸入治疗的有 493 人,接受率为 74.02%;监护人用药知识、态度和行为的平均得分均处于良好水平;单因素分析显示不同的监护人年龄、居住地、教育程度、职业、来医院单程时间、患儿医保和诊断情况在监护人用药知识得分中的差异具有统计学意义(P<0.05),不同的监护人年龄、居住地、教育程度、职业、来医院单程时间、患儿的年龄和诊断情况在监护人用药态度得分中的差异具有统计学意义(P<0.05),不同的监护人与孩子的关系、年龄、居住地、教育程度、职业、来医院单程时间,以及患儿年龄、医保情况和诊断情况在监护人用药行为得分中的差异具有统计学意义(P<0.05);多重线性回归分析结果显示,影响居家雾化用药知识得分的因素是监护人年龄、居住地、教育程度、来医院单程时间和患儿医保情况(P<0.05),影响居家雾化用药态度得分的因素有监护人年龄、居住地、教育程度、来医院单程时间和患儿的诊断(P<0.05),影响居家雾化用药行为得分的因素有居住地、职业和来医院单程时间(P<0.05)。结论: 河南地区喘息性疾病患儿监护人对居家雾化治疗的接受度较高,多数监护人对安全用药知识、态度与行为的掌握情况良好;未来健康宣教应重点关注老年人、低学历和自由职业者等群体,实施个性化干预以提升居家雾化用药安全。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1222-1226. https://doi.org/10.13493/j.issn.1672-7878.2025.12-006
    目的: 分析医院 2020—2024 年所上报的中药制剂相关药物不良反应(adverse drug reactions,ADRs)的流行病学特点,为临床合理用药提供参考。方法: 选取 2020—2024 年苏州市中西医结合医院上报至国家药品不良反应监测中心的 171 例中药制剂相关的 ADRs 报告作为研究资料,收集 ADRs 的报告类型,ADRs 报告所涉患者性别和年龄、中药制剂种类、给药途径,以及 ADRs 累及器官(或系统)和临床表现,分析中药制剂相关 ADRs 的流行病学特点。结果: 2020—2024 年,医院上报的中药制剂相关 ADRs 报告类型为“一般”的 83 例(占 48.54%),为“严重”的 56 例(占 32.75%);所涉患者男性与女性数量相当(88 例 vs 83 例);患者年龄以>60 岁为主(63 例,占 36.84%),其次为>45~60 岁(51 例,占 29.82%);所涉中药制剂按功效分类,主要为活血类(87 例,占 49.15%),其次为清热类(41 例,占 23.16%);所涉药品品种主要为注射用血栓通(冻干)(18 例,占 10.17%)、舒肝宁注射液(17 例,占 9.60%),以及参麦注射液(13 例,占 7.34%);所涉中药制剂的给药方式主要为静脉给药(105 例,占 59.32%),其次为口服给药(50 例,占 28.25%);ADRs 以累及皮肤及其附件的发生率最高(100 例,发生率 58.48%),其次为心血管系统(30 例,发生率 17.54%)。结论: 患者年龄、给药途径、药品种类等方面有着较明显的特点,临床应加强对中老年、有过敏史或肝肾功能异常患者的用药监护与教育,并完善 ADRs 监测体系,以提升用药安全水平。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1276-1279. https://doi.org/10.13493/j.issn.1672-7878.2025.12-015
    目的: 分析老年股骨骨折患者术后并发肺部感染的影响因素,为老年股骨骨折患者术后感染的预防提供参考。方法: 选取 2020 年 3 月—2024 年 3 月平顶山市中医医院收治的 80 例老年股骨骨折患者作为研究对象,采集所有患者的年龄、性别、婚姻状况、吸烟史、饮酒史、基础疾病、手术时长、手术类型、住院时长等信息,以及老年股骨骨折患者术后肺部感染的发生情况,分析发生术后肺部感染的影响因素。结果: 80 例患者术后共有 16 例(占 20.00%)发生肺部感染;单因素分析结果显示,年龄、糖尿病史、低蛋白血症、意识障碍、吞咽障碍、住院时长、入住 ICU、侵入性操作与老年股骨骨折患者术后发生肺部感染相关(P<0.05);Logistic 回归分析结果显示,年龄>75 岁(OR=3.413,95%CI 为 1.093~10.657)、有糖尿病史(OR=11.074,95%CI 为 2.818~43.517)、有低蛋白血症(OR=3.413,95%CI 为 1.093~10.657)、有意识障碍(OR=6.600,95%CI 为 1.893~23.012)、有吞咽障碍(OR=5.211,95%CI 为 1.593~17.048)、住院时长≥2 周(OR=4.200,95%CI 为 1.295~13.617)、入住 ICU(OR=4.385,95%CI 为 1.273~15.101)、有侵入性操作(OR=3.922,95%CI 为 1.212~12.686)为老年股骨骨折患者术后发生肺部感染的独立危险因素(P<0.05)。结论: 年龄>75 岁、有糖尿病史、有低蛋白血症、有意识障碍、有吞咽障碍、住院时长≥2 周、入住 ICU、有侵入性操作为老年股骨骨折患者术后发生肺部感染的危险因素,临床需据此制定相关预防措施。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1245-1249. https://doi.org/10.13493/j.issn.1672-7878.2025.12-010
    目的: 分析 PDSA 在降低住院患者抗菌药物使用强度(antibiotics use density,AUD)中的效果,为临床抗菌药物的合理应用与管理提供参考。方法: 选取 2024 年 1—12 月医院住院患者抗菌药物使用情况作为研究资料,将 2024 年 1—3 月实施 PDSA 前的资料设为实施前组,2024 年 4—12 月的设为实施后组,分析实施 PDSA 前后全院各科室 AUD 达标情况和抗菌药物使用率的变化情况。结果: 实施 PDSA 的持续改进项目后,临床科室 AUD 未达标数量呈下降趋势,不达标率最低降至 7.14%;全院 28 个临床科室中 21 个科室 AUD 较实施前降低;医院住院患者 AUD 也有所下降,2024 年 4 月下降至 38.03,整体 AUD 均在目标值以下,最低为 28.66;2024 年全年 AUD 为 33.94,较 2023 年度 AUD 值 35.91 下降 5.49%;医院住院患者抗菌药物使用率下降明显,始终维持在目标值以内,最低降至 42.13%。结论: 通过实施 PDSA 显著降低住院患者 AUD 和抗菌药物的使用率,均达到国家三级公立医院的标准,促进了抗菌药物的临床合理应用。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1227-1231. https://doi.org/10.13493/j.issn.1672-7878.2025.12-007
    目的: 分析 2023 年苏州市第九人民医院上报药物不良反应(adverse drug reactions,ADRs)的流行病学特征,为临床安全合理用药提供参考。方法: 选取 2023 年 1—12 月苏州市第九人民医院上报至国家药品不良反应监测系统的 612 例 ADRs 报告作为研究资料,对报告类型、患者性别和年龄、涉及药物类别与剂型、累及器官(或系统)等数据进行统计分析。结果: 612 例 ADRs 报告中,报告类型以“一般”为主(440 例,占 71.90%),其后依次为“严重”(101 例,占 16.50%)、“新的一般”(65 例,占 10.62%)和“新的严重”(6 例,占 0.98%);ADRs 报告所涉女性患者(311 例,占 50.82%)略多于男性患者(301 例,占 49.18%);患者年龄以>65 岁居多(289 例,占 47.22%),其次为>45~65 岁(203 例,占 33.17%);ADRs 所涉主要的药物类别为抗感染药物(196 例,占 32.03%)和抗肿瘤药物(124 例,占 20.26%);所涉药物的剂型主要为注射剂(345 例,占 56.37%)和粉针剂(138 例,占 22.55%);ADRs 最常累及器官(或系统)为皮肤及其附件(201 例,占 32.84%),其次为消化系统(165 例,占 26.96%)。结论: 医院 2023 年上报的 ADRs 具有老年患者多发、抗感染与抗肿瘤药物风险突出、静脉给药为主要风险途径、累及器官(或系统)以皮肤及其附件和消化系统为主等特征;建议加强对老年患者和重点药物的用药监护,规范静脉给药操作,并持续强化对“新的”和“严重”ADRs 的监测与上报,以提升用药安全水平。
  • SHI Juan, HAN Jin-cai, SHI Guang-wei, YANG He, ZENG Jun-yuan, YANG Yan-mei
    KANGGANRAN YAOXUE. 2025, 22(12): 1209-1214. https://doi.org/10.13493/j.issn.1672-7878.2025.12-004
    Objective: To analyze the anti-infective therapy and pharmaceutical care process of a patient with liver abscess complicated by pulmonary infection, and provide a reference for the clinical treatment of such patients. Methods and Results: A patient was admitted with headache, generalized soreness, cough and expectoration, nausea, vomiting, abdominal pain, high fever and chills. The admitting diagnoses were ''pulmonary infection'' and ''acute bronchitis'', and cefotaxime sodium was used for initial anti-infective therapy. As the infection continued to aggravate during treatment, the medication was adjusted to cefoperazone-sulbactam sodium (cefoperazone: sulbactam = 1:1, 3 g, q12h, intravenous infusion) after pharmacist consultation. On the 5th day of admission, the patient's symptoms still did not improve and infection indicators increased; after communication between pharmacists and physicians, the anti-infective therapeutic regimen was adjusted to cefoperazone-sulbactam sodium (cefoperazone: sulbactam = 2:1, 3 g, q8h, intravenous infusion) plus levofloxacin injection. On the 8th day of admission, the patient suffered from severe epigastric pain. Contrast-enhanced abdominal CT revealed a space-occupying lesion in the left hepatic lobe, highly suggestive of liver abscess. The clinical diagnosis of ''liver abscess'' was added, and percutaneous puncture and catheter drainage of the liver abscess was performed on the same day, without adjustment of the anti-infective therapeutic regimen. On the 13th day of admission, the patient developed bitter mouth, dry mouth, abdominal distension, abdominal pain, chest tightness and shortness of breath, and was given domperidone tablets, phloroglucinol injection and Zhichuanling Injection for symptomatic treatment. On the first day of this treatment, the patient presented with involuntary hand movement, restlessness, hallucination and impulsive behavior. After correlation analysis of adverse drug reactions, the pharmacist recommended discontinuing domperidone tablets, Zhichuanling Injection and levofloxacin and sodium chloride injection; the neurological symptoms resolved completely after drug withdrawal. On the 22nd day of admission, the patient's symptoms and laboratory findings improved significantly, and discharge was approved. The clinical pharmacist provided discharge medication advice, recommending amoxicillin-clavulanate potassium tablets plus metronidazole tablets. Conclusion: Through participation in the treatment and medication monitoring of a patient with liver abscess complicated by pulmonary infection, clinical pharmacists have adjusted anti-infective agents, identified and managed adverse drug reactions in a timely manner, thereby improving therapeutic efficacy and ensuring medication safety.
  • ZHENG Li-xia
    KANGGANRAN YAOXUE. 2026, 23(4): 339-344. https://doi.org/10.13493/j.issn.1672-7878.2026.04-003
    Objective: To analyze the anti-infective therapy and pharmaceutical care of a patient with carbapenem-resistant Gram-negative bacterial infection after craniocerebral injury surgery, and provide a reference for rational clinical drug use. Methods and Results: The patient underwent intracranial hematoma evacuation and decompressive craniectomy for multiple cerebral contusions and lacerations, and developed persistent high fever after surgery. After admission to the ICU, sputum culture, blood culture and drug susceptibility tests all indicated multidrug-resistant Acinetobacter baumannii, which was sensitive to tigecycline and polymyxin E. Clinical pharmacists participated in the treatment. The initial regimen was tigecycline intravenous infusion combined with intravenous infusion and aerosol inhalation of colistimethate sodium. Later, cerebrospinal fluid culture and drug susceptibility test confirmed multidrug-resistant Acinetobacter baumannii. For the intracranial infection, intrathecal injection of polymyxin E and tigecycline was administered, and the infection was partially controlled. Subsequently, due to renal injury (creatinine clearance rate decreased to 31.71 mL/min), abnormal liver function (total bilirubin 47.0 μmol/L) and coagulation dysfunction, the doses of polymyxin E and tigecycline were adjusted or the drugs were discontinued respectively. Afterwards, cerebrospinal fluid culture turned positive for Enterobacter cloacae. Drug susceptibility tests showed that the strain was resistant to ceftazidime-avibactam sodium but sensitive to aztreonam. Clinical pharmacists recommended ceftazidime-avibactam sodium combined with aztreonam, and the infection was brought under control. During treatment, the dosage regimen was adjusted in a timely manner through therapeutic drug monitoring and dynamic monitoring of hepatorenal function and coagulation function. Eventually, the patient's intracranial infection improved, and the patient was transferred to the department of neurosurgery for hydrocephalus shunt surgery. Conclusion: The treatment is difficult for intracranial infection caused by carbapenem-resistant Gram-negative bacteria after craniocerebral injury surgery. Individualized combination anti-infective regimens should be formulated based on drug susceptibility results, blood-brain barrier permeability and adverse drug reaction monitoring. The full participation of clinical pharmacists helps optimize medication, reduce toxicity and improve patient prognosis.
  • KANGGANRAN YAOXUE. 2025, 22(12): 1271-1275. https://doi.org/10.13493/j.issn.1672-7878.2025.12-014
    目的: 分析糖尿病患者行前列腺切除术后发生尿路感染的危险因素,并提出相应干预对策,为糖尿病患者行前列腺切除术后发生尿路感染的预防提供参考。方法: 选取 2019 年 1 月—2023 年 12 月于都县人民医院收治的 102 例接受前列腺切除术治疗的糖尿病患者作为研究对象,采集患者的性别、年龄、吸烟史、饮酒史、文化程度、身体质量指数、合并高血压情况、术前空腹血糖、术前尿培养结果、手术时长、术前行导尿术和术前预防性使用抗菌药物情况等;依据术后尿路感染发生情况将其分为感染发生组和未发生组,采用 Logistic 回归分析法分析糖尿病患者行前列腺切除术后发生尿路感染的危险因素。结果: 102 例患者术后有 22 例(占 21.57%)发生尿路感染(设为发生组),80 例(占 78.43%)未发生尿路感染(设为未发生组);年龄、术前空腹血糖、手术时长、术前行导尿术和术前使用抗菌药物情况与糖尿病患者前列腺切除术后尿路感染相关(P<0.05);经 Logistic 回归分析,年龄大、术前空腹血糖高、手术时长长、术前行导尿术和术前未预防性使用抗菌药物均为糖尿病患者前列腺切除术后尿路感染的危险因素(OR>1,P<0.05)。结论: 糖尿病患者行前列腺切除术后发生尿路感染的危险因素为年龄大、术前空腹血糖高、手术时长长、术前行导尿术和术前未预防性使用抗菌药物,临床需据此采取有效的干预对策,以减少或避免术后尿路感染的发生。
  • KANGGANRAN YAOXUE. 2025, 22(12): 1286-1289. https://doi.org/10.13493/j.issn.1672-7878.2025.12-017
    目的: 分析苏州地区妊娠晚期妇女 B 族链球菌(group B Streptococcus,GBS)的感染情况,并探讨不同年龄、血型、阴道环境对妊娠晚期孕妇 GBS 感染的影响,为该地区孕妇 GBS 感染的早期预防和高危人群筛查提供循证依据。方法: 选取 2018 年 1 月—12 月在医院产科门诊产检的 7 769 例妊娠晚期妇女作为研究对象,采集其阴道下 1/3 分泌物和直肠分泌物,采用 GBS 专用选择性显色培养基进行培养鉴定,分析孕妇年龄、血型、阴道环境与 GBS 阳性率的关系。结果: 共纳入 7 769 例孕妇,其中 GBS 阳性者 620 例,总阳性率为 7.98%;按年龄段分析结果显示,>39 岁年龄段孕妇 GBS 阳性率最高(12.12%),其次为>29~34 岁年龄段(8.62%),各年龄段 GBS 阳性率差异无统计学意义(χ2=3.92,P=0.42);按血型分析结果显示,A 型、B 型、AB 型、O 型血孕妇 GBS 阳性率分别为 7.64%、8.64%、6.67%、8.31%,Rh 阳性、阴性血型孕妇 GBS 阳性率分别 8.01%、3.70%,不同血型的孕妇 GBS 阳性率差异无统计学意义(P>0.05);阴道微生态和炎症指标分析结果显示,阴道分泌物检出霉菌的妊娠晚期妇女 GBS 阳性率显著高于未见霉菌者(10.57% vs 7.82%,P=0.04);妊娠晚期妇女 GBS 感染与阴道分泌物滴虫、白细胞计数、上皮细胞计数和阴道清洁度均无相关性(均 P>0.05)。结论: 妊娠晚期妇女 GBS 感染与阴道霉菌感染相关,孕妇在备孕和怀孕期间应该严格注意阴道清洁卫生,尤其注意避免霉菌感染。
  • KANGGANRAN YAOXUE. 2026, 23(5): 490-497. https://doi.org/10.13493/j.issn.1672-7878.2026.05-013
    目的:对 16 种临床常用治疗气虚血瘀型脑卒中的中成药进行多维度综合量化评价,明确各品种的综合应用价值,为医疗机构脑卒中中成药目录遴选、临床合理用药和药品精细化管理提供客观参考依据。方法:以《医疗机构中成药遴选专家共识(第一版)》为核心评价依据,从安全性、有效性、经济性、创新性、适宜性、可及性、传承性七大维度构建评价体系,采用定性与定量相结合的方法对纳入的 16 种中成药进行百分制量化评分和综合分析。结果:16 种治疗气虚血瘀型脑卒中中成药的综合评分排名前三位的品种依次为通心络胶囊(72.5 分)、脑心通胶囊(72 分)和脑安滴丸(62.8 分),上述品种在多维度综合表现更优,提示其临床应用具有一定优势;其余中成药各维度评价结果存在明显差异,部分品种在部分维度得分较低。结论:目前临床用于治疗气虚血瘀型脑卒中的多数中成药仍存在特殊人群用药研究匮乏、药代动力学数据缺失、上市后再评价体系不完善、药物经济学证据不足等问题;本研究为阶段性静态评价结果,随着中成药研究数据的积累、循证证据的更新和药品质量评价体系的不断完善,后续可开展动态化、持续性的综合评估,为进一步优化脑卒中中成药的临床遴选与合理应用方案提供参考。
  • PENG Yan-qiong
    KANGGANRAN YAOXUE. 2026, 23(4): 345-347. https://doi.org/10.13493/j.issn.1672-7878.2026.04-004
    Objective: To analyze the occurrence and management process of severe adverse drug reactions (ADRs) induced by cefotaxime-sulbactam sodium, and provide a reference for the clinical medication safety of this agent. Methods and Results: A patient was admitted due to "36+4 weeks of gestation, lower abdominal distending pain with vaginal fluid leakage for 1 hour" and underwent cesarean section. Postoperatively, the patient presented with fever and elevated infection markers, which suggested bacterial infection. Cefotaxime-sulbactam sodium (1.5 g, q8h) was initiated for anti-infective therapy. Due to recurrent fever, the dose was adjusted to 2.25 g per dose 8 hours later. On the next day, the patient suddenly developed frisson, tachypnea, chest tightness and palpitations, with unmeasurable blood pressure, followed by hypertensive crisis and hyperthermia up to 40℃. The symptoms were relieved after symptomatic treatment. On the afternoon of the same day, the patient redeveloped chest tightness and palpitations during the administration of cefotaxime-sulbactam sodium. The symptoms were suspected to be ADRs induced by the drug. After immediate discontinuation and switching to an alternative anti-infective regimen, no further discomfort occurred. Conclusion: The severe ADRs in this patient following cefotaxime-sulbactam sodium administration involved the respiratory and cardiovascular systems. Clinical monitoring of ADRs should be strengthened during the use of this drug, and vigilance against severe ADRs is required for special populations (such as peripartum women) and after dose adjustment, so as to ensure medication safety of patients.
  • ZHANG Wen-ying, Li Jia, ZHENG Yan-lin, ZHOU Qiao-ling, CHEN Jie
    KANGGANRAN YAOXUE. 2026, 23(4): 366-377. https://doi.org/10.13493/j.issn.1672-7878.2026.04-008
    Objective: To comprehensively evaluate the clinical value of injectable nitroimidazoles, and provide a reference for drug selection and rational use of such drugs in medical institutions. Methods: Based on the quantitative evaluation and selection record form specified in the Rapid Guideline for Drug Evaluation and Selection in Chinese Medical Institutions (the Third Edition) (hereinafter referred to as the Selection Guideline), evaluation evidence was collected. A comprehensive evaluation was conducted on 7 preparations from five dimensions: effectiveness, safety, pharmaceutical properties, cost-effectiveness and other attributes. The preparations included metronidazole and sodium chloride injection (Baxter Healthcare (Shanghai) Co., Ltd.), metronidazole and sodium chloride injection (Huiyinbi Group Jiangxi Dongya Pharmaceutical Co., Ltd.), tinidazole and sodium chloride injection, ornidazole injection, levornidazole disodium phosphate for injection, morphinidazole and sodium chloride injection (Jiangsu Hansoh Pharmaceutical Group Co., Ltd.), and morphinidazole and sodium chloride injection (Shandong Qidu Pharmaceutical Co., Ltd.). Results: The quantitative scores of the above drugs in descending order were as follows: ornidazole injection (Shijiazhuang No.4 Pharmaceutical Co., Ltd., 79.8 points), metronidazole and sodium chloride injection (Huiyinbi Group Jiangxi Dongya Pharmaceutical Co., Ltd., 67.9 points), metronidazole and sodium chloride injection (Baxter Healthcare (Shanghai) Co., Ltd., 67.5 points), tinidazole and sodium chloride injection (Sichuan Meidakang Jiale Pharmaceutical Co., Ltd., 65.2 points), levornidazole disodium phosphate for injection (Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co., Ltd., 54.5 points), morphinidazole and sodium chloride injection (Jiangsu Hansoh Pharmaceutical Group Co., Ltd., 49.4 points), and morphinidazole and sodium chloride injection (Shandong Qidu Pharmaceutical Co., Ltd., 48.6 points). Conclusion: With favorable performance in safety and cost-effectiveness, ornidazole injection, together with metronidazole and sodium chloride injection, are the priority choices for medical institutions in the selection of injectable nitroimidazoles. The comprehensive evaluation results based on the Selection Guideline can provide a reference for the selection and rational clinical use of such drugs in medical institutions.
  • ZHANG Pei, HAN Jia-lin, LI Nan
    KANGGANRAN YAOXUE. 2025, 22(12): 1232-1236. https://doi.org/10.13493/j.issn.1672-7878.2025.12-008
    Objective: To establish a risk prediction model for high plasma concentration of doxycycline in children aged 8-18 years with Mycoplasma pneumoniae pneumonia (MMP), so as to provide a basis for clinically precise adjustment of dosage regimens. Methods: A retrospective cohort study was performed. Clinical data were collected from children aged 8-18 years with MPP who received doxycycline treatment in The First People's Hospital of Zhengzhou from April 2023 to April 2024. Steady-state plasma concentration on day 7 was measured (with not less than 1.5 mg/L defined as high concentration). Univariate and multivariate Logistic regression analysis was used to screen risk factors and establish the prediction equation. Receiver operating characteristic (ROC) curve was utilized to evaluate model performance including area under curve (AUC), sensitivity, specificity and other indicators. Results: A total of 117 children were enrolled (29 in the high-concentration group, 88 in the low-concentration group). Multivariate analysis results showed that body weight (OR=1.117, 95%CI: 1.052-1.186), alanine transaminase (ALT) (OR=0.914, 95%CI: 0.856-0.976) and estimated glomerular filtration rate (eGFR) (OR=1.063, 95%CI: 1.018-1.110) were independent influencing factors for high plasma concentration of doxycycline in children with MMP. The prediction model equation was: logit (P) = 0.111 × body weight (kg) - 0.090 × ALT (U/L) + 0.061 × eGFR (mL/(min·1.73 m2)) - 1.856. The model achieved AUC of 0.915 (95%CI: 0.853-0.978), sensitivity of 0.929, specificity of 0.966, accuracy of 0.957 and Youden index of 0.895. The Hosmer-Lemeshow test indicated good model calibration (P=0.823). Conclusion: The prediction model constructed in this study presents high predictive performance for high plasma concentration of doxycycline in children aged 8-18 years with MMP, and may provide a reference for individualized clinical dosing regimens.
  • WU Yan, GAO Ting, MA Li, XIONG Shi-juan
    KANGGANRAN YAOXUE. 2026, 23(4): 334-338. https://doi.org/10.13493/j.issn.1672-7878.2026.04-002
    Objective: To analyze the anti-infective treatment regimen for a patient with Brucella bloodstream infection complicated by liver cirrhosis, explore the selection and adjustment of anti-infective regimens in patients with moderate to severe hepatic insufficiency, and provide a reference for individualized treatment of similar cases. Methods and Results: A 54-year-old male patient with a history of cattle and sheep rearing was admitted due to "recurrent fever accompanied by cough and low back pain", with a prior diagnosis of decompensated cirrhosis. Brucella infection was confirmed by blood culture after admission. The initial anti-infective regimen was doxycycline combined with rifampicin. After 4 days of treatment, the patient's bilirubin levels increased progressively (with total bilirubin rising to 34.6 μmol/L and direct bilirubin to 22.4 μmol/L). Rifampicin-associated hepatotoxicity was suspected, thus, rifampicin was discontinued, the regimen was switched to doxycycline monotherapy, and ursodeoxycholic acid was added. Bilirubin levels decreased significantly after drug withdrawal. The patient was discharged with prescribed medications after his condition stabilized. One week after discharge, the patient developed low-grade fever and low back pain again, and received anti-infective therapy with levofloxacin plus doxycycline at a local hospital, with symptoms gradually relieved. Conclusion: For the anti-infective treatment of Brucella infection complicated with hepatic insufficiency, a balance between therapeutic efficacy and drug safety should be achieved. The combination of rifampicin and doxycycline is a commonly used regimen, but it may aggravate liver injury, while monotherapy is associated with a higher risk of recurrence. In clinical practice, combination regimens with lower hepatotoxicity should be prioritized based on the patient's liver function, and liver function monitoring as well as pharmaceutical care should be strengthened throughout the treatment course.
  • WANG Yu, CHEN Yuan-mei, ZHU Li, ZHU Chuan-wu
    KANGGANRAN YAOXUE. 2026, 23(4): 329-333. https://doi.org/10.13493/j.issn.1672-7878.2026.04-001
    During hepatitis B virus (HBV) infection, protein ubiquitination plays a pivotal role in host immune regulation and viral replication. By reversing protein ubiquitination, deubiquitinating enzyme (DUB) modulate the localization, metabolism and degradation of viral proteins, and further regulate HBV replication and clearance. This article systematically summarizes the functional mechanism of DUB in regulating HBV infection via protein ubiquitination, elucidates the intricate regulatory network between viral immune evasion and host immune defense, provides new ideas for the research and development of antiviral agents, and facilitates the clinical cure of chronic hepatitis B.
  • KANGGANRAN YAOXUE. 2026, 23(4): 427-432. https://doi.org/10.13493/j.issn.1672-7878.2026.04-017
    目的:分析近年来医院就诊患者泌尿生殖道支原体检出情况及其耐药性,为临床治疗提供参考。方法:选取 2018 年 1 月—2024 年 8 月于河南省第二人民医院就诊的疑似泌尿生殖道感染的 19 881 例患者作为研究对象,采集其泌尿生殖道标本进行支原体检测与药敏试验。结果:19 881 例患者中,支原体感染总阳性率为45.00%(8 947/19 881),单纯性解脲脲原体(Ureaplasma urealyticum,Uu)感染、单纯性人型支原体(Mycoplasma hominis,Mh)感染和 Uu+Mh 混合感染的阳性率分别为 36.66%(7 288/19 881)、1.05%(208/19 881)和 7.30%(1 451/19 881);7 458 例男性患者的支原体感染总阳性率为 29.66%(2 212/7 458),单纯性 Uu 感染、单纯性 Mh 感染和 Uu+Mh 混合感染阳性率分别为 25.77%(1 922/7 458)、0.82%(61/7 458)和 3.07%(229/7 458);12 423 例女性患者的支原体感染总阳性率为 54.21%(6 735/12 423),单纯性 Uu 感染、单纯性 Mh 感染和 Uu+Mh 混合感染阳性率分别为 43.19%(5 366/12 423)、1.18%(147/12 423)和 9.84%(1 222/12 423),不同性别,支原体感染总阳性率、单纯性 Uu 感染阳性率、Uu+Mh 混合感染阳性率之间差异均有统计学意义(P<0.05);>20~30 岁和>30~40 岁年龄段患者人数较多,分别为 7 867 例和 7 107 例,>40~50 岁患者的支原体感染总阳性率最高,为 48.71%(1 055/2 166),>20~30 岁的单纯性 Uu 感染阳性率最高,>50~60 岁的单纯性 Mh 感染阳性率最高,>40~50 岁的 Uu+Mh 混合感染阳性率最高,不同年龄段间支原体感染总阳性率与单纯性 Uu 感染阳性率的差异均有统计学意义(P<0.05);不同支原体感染类型标本对多西环素、米诺环素和交沙霉素的敏感率均较高(>97.00%),单纯性 Uu 感染标本对克林霉素的耐药率较高(77.39%),单纯性 Mh 感染标本对阿奇霉素、泰利霉素、红霉素和克拉霉素的耐药率较高(均>85.00%),Uu+Mh 混合感染标本对克林霉素、阿奇霉素、泰利霉素和克拉霉素的耐药率亦较高(均>85.00%)。结论:医院泌尿生殖道支原体感染以单纯性 Uu 感染为主,不同性别、不同年龄段患者的支原体感染类型分布存在差异,不同感染类型和同一感染类型对同类不同种抗菌药物的耐药性亦存在差异;临床应依据药敏试验结果合理选用抗菌药物,并加强支原体感染的健康宣教,提高公众卫生健康意识。
  • CHEN Lin-lin, ZHANG Ya-jing, JIA Xiao-meng, BAO Chong-yang
    KANGGANRAN YAOXUE. 2026, 23(5): 433-437. https://doi.org/10.13493/j.issn.1672-7878.2026.05-001
    Drug-resistant tuberculosis is a key priority and major challenge in tuberculosis prevention and control in China. Conventional fixed-dose regimens often overlook factors including interindividual pharmacokinetic variability, strain-specific drug resistance profiles, and underlying diseases, which readily leads to adverse outcomes: insufficient bactericidal efficacy, acquired drug resistance, disease recurrence, and drug accumulation-induced toxicity. With the popularization of novel anti-tuberculosis agents and the maturation of therapeutic drug monitoring technology, the diagnostic and therapeutic pattern for drug-resistant tuberculosis has gradually shifted from standardized therapy to individualized precision therapy. This paper reviews the advantages and existing limitations of current precision diagnosis and treatment, aiming to provide evidence-based references for optimizing individualized treatment regimens for drug-resistant tuberculosis, improving treatment success rates, and reducing the incidence of adverse drug reactions.
  • WANG Pei-hong, ZHANG Yin
    KANGGANRAN YAOXUE. 2026, 23(4): 378-383. https://doi.org/10.13493/j.issn.1672-7878.2026.04-009
    Amphotericin B is an irreplaceable broad-spectrum antifungal drug for the treatment of invasive fungal diseases, yet nephrotoxicity remains its major dose-limiting adverse drug reaction, which severely restricts its clinical application. This article summarizes the pathogenesis of nephrotoxicity induced by amphotericin B deoxycholate and liposomal formulations, involving multiple pathways including direct renal tubular injury, renal vasoconstriction and oxidative stress. It focuses on the nephroprotective mechanism of liposomal formulations, achieved through pharmacokinetic advantages such as targeting the mononuclear phagocyte system and reducing free drug concentration in the kidney. Furthermore, clinical management strategies are summarized from multiple aspects, including risk assessment, hydration and volume expansion, infusion time optimization, dose and dosing interval adjustment, and combination with low-nephrotoxicity drugs. This article aims to provide a theoretical basis for the safe clinical use of amphotericin B and the optimization of individualized treatment regimens.
  • KANGGANRAN YAOXUE. 2025, 22(12): 1280-1285. https://doi.org/10.13493/j.issn.1672-7878.2025.12-016
    目的: 分析医院肺结核患者的耐药现状与发生耐药的影响因素,为肺结核防控提供科学依据。方法: 选取 2023 年 1 月—2024 年 1 月郑州市第六人民医院收治的 921 例肺结核患者为研究对象,予施行痰培养及其药敏试验,根据检出病原菌耐药情况将其分为耐药组和敏感组,从医院信息系统(hospital information system,HIS)收集肺结核患者的性别、年龄、身体质量指数(body mass index,BMI)、民族、人口类型、婚姻状况、职业、吸烟史、饮酒史、有无合并糖尿病、有无合并高血压、肺结核接触史、肺结核治疗史等,分析初治、复治肺结核患者标本检出结核分枝杆菌的药敏结果,比较耐药组与敏感组所涉患者的临床资料,以及肺结核患者的病原菌耐药的危险因素。结果: 921 例肺结核患者标本检出 921 株结核分枝杆菌,其中有 255 株耐药(占 27.69%),归为耐药组,其余 666 株归为敏感组;结核分枝杆菌的耐多药率较高(11.29%),对一线抗结核药物的耐药率由高到低依次为异烟肼、链霉素、利福平、乙胺丁醇,对二线抗结核药物耐药率排名前 3 位的为左氧氟沙星、莫西沙星、对氨基水杨酸,复治肺结核患者(n=185)标本检出的病原菌对异烟肼、链霉素、利福平、左氧氟沙星、莫西沙星、阿米卡星的耐药率,以及总耐药率、多耐药率、耐多药率、广泛耐药率均高于初治肺结核患者(n=736)(P<0.05);耐药组所涉患者年龄 45~60 岁、合并糖尿病、有肺结核接触史、复治肺结核、咳嗽咳痰时间≥3 周、有咯血、双肺受累肺野数为 6 个、有肺结核空洞患者的构成比高于敏感组(P<0.05);Logistic 回归分析结果显示,年龄 45~60 岁、有肺结核接触史、复治肺结核、双肺受累肺野数 6 个、有肺结核空洞均是结核分枝杆菌耐药的危险因素(P<0.05)。结论: 921 例肺结核患者的病原菌耐药率为 27.69%,其中耐多药率较高,复治患者的耐药率较高,需加以重视;另年龄 45~60 岁、有肺结核接触史、复治肺结核、双肺受累肺野数为 6 个、有肺结核空洞是肺结核患者的病原菌耐药的危险因素。
  • KANGGANRAN YAOXUE. 2026, 23(4): 402-406. https://doi.org/10.13493/j.issn.1672-7878.2026.04-013
    目的:分析医院静脉用药调配中心(pharmacy intravenous admixture services,PIVAS)不合理医嘱的类型,并提出针对性干预策略,为提升审方质量、保障静脉用药安全提供依据。方法:选取 2024 年 1—12 月个旧市人民医院 PIVAS 接收的 534 361 条静脉用药医嘱作为研究资料,依据药品说明书、临床用药指南和相关规范,对医嘱进行点评分析。结果:共审核静脉用药医嘱 534 361 条,发现不合理医嘱 262 条,不合理率为 0.05%;主要不合理类型为用法用量不适宜(92 条,占 35.11%)、溶媒选择不适宜(56 条,占 21.37%)、给药浓度不适宜(43 条,占 16.41%)。结论:医院不合理医嘱涵盖用法用量不适宜、溶媒选择不适宜、给药浓度不适宜等多种类型,针对上述问题,本研究从系统审核体系优化、药师专业能力提升和医药协作沟通强化等维度提出了综合干预策略,为 PIVAS 审方质量的持续改进提供参考。
  • KANGGANRAN YAOXUE. 2026, 23(4): 407-413. https://doi.org/10.13493/j.issn.1672-7878.2026.04-014
    目的:基于 CiteSpace 和 VOSviewer 工具,对中药地肤子研究热点变化进行可视化分析,为拓展其临床使用范围与药用价值开发提供参考。方法:检索中国知网、万方数据库、维普中文科技期刊数据库和中国生物医学文献服务系统(SinoMed),以“地肤子”为主题词,检索时间范围为 1995 年 1 月 1 日—2025 年 12 月 31 日,纳入相关期刊文献;采用 CiteSpace 和 VOSviewer 等软件,对发文量、研究机构、期刊分布、核心作者和关键词等进行文献计量学与可视化分析。结果:共纳入中文文献 657 篇,年度发文量于 1997 年达到峰值(50 篇),2015 年后呈下降趋势;基于 CiteSpace 的机构合作网络分析结果显示,地肤子研究领域共包含 603 个节点与 167 条连线,网络密度为 0.000 9,机构间的合作关联相对薄弱;发文最多的机构为中国药科大学(12 篇);主要发文期刊为《陕西中医》(48 篇);采用 VOSviewer 对发文频次前 100 位的作者节点进行分析,结果显示地肤子研究领域的作者合作网络呈现多聚类与弱关联的结构特征,该网络共包含 18 个聚类和 276 条连线,总连接强度为 434;地肤子相关文献的核心作者主要为戴岳(10 篇,总连接强度 20)、夏玉凤(8 篇,总连接强度为 13)、曹挥(6 篇,总连接强度为 15);关键词共现网络包含 538 个节点与 1 199 条连线,网络密度为 0.008 3,“地肤子”频次(131 次)与中心性(0.95)均居首位;聚类分析生成 13 个主题聚类(Q=0.720 6,S=0.930 3),核心聚类为“#0 地肤子”,衍生出适用病症、应用方式、临床研究、配伍药物和基础研究等方向;关键词突现与时间线分析显示,研究热点从早期“临床疗效观察”逐步向“化学成分”“质量标准”等方向演变。结论:近 30 年地肤子研究以临床疗效评价为核心,但基础研究相对薄弱,机构和作者间缺乏广泛合作,研究热点正从经验性临床观察向作用机制与质量控制方向演变;未来应加强跨学科协作,深入探究其药效机制,并建立标准化质量控制体系。
  • HUANG Wei-bin, CHEN Pei-shan
    KANGGANRAN YAOXUE. 2026, 23(5): 453-455. https://doi.org/10.13493/j.issn.1672-7878.2026.05-005
    Objective: To analyze the adverse drug reaction identification process in a patient with neutropenia induced by piperacillin-tazobactam sodium, so as to provide a reference for clinical medication safety and adverse drug reaction monitoring. Methodsand Results: A patient was admitted due to "recurrent cough, fever, abdominal distension and nausea for over half a month". Empirical treatment with amoxicillin-clavulanate potassium (1.2 g, q12h, intravenous infusion) was initiated. After 2 days, fever persisted with severe cough and expectoration, so the regimen was switched to piperacillin-tazobactam sodium (4.5 g, q8h, intravenous infusion). On day 16 of medication, clinical pharmacists observed a decline in neutrophil count and conducted a multi-dimensional analysis with the attending physician. On day 18, neutrophil count dropped to 0.61×109/L despite improved clinical symptoms, which was judged as an adverse drug reaction. After reviewing medication orders and temporal correlation, pharmacists recommended discontinuing piperacillin-tazobactam sodium and adding human granulocyte colony-stimulating factor. Three days later, neutrophil count returned to normal. Conclusion: With professional sensitivity, clinical pharmacists completed the overall process from detection, analysis, intervention to adverse drug reaction reporting, enabling timely and effective treatment and smooth discharge of the patient. This case demonstrates the role of clinical pharmacists in the treatment team and in safeguarding medication safety for patients.
  • FAN Wei-wei, CUI Wei-yan, YANG Yu-ya, LI Jie, ZHU Chun-xiang
    KANGGANRAN YAOXUE. 2026, 23(5): 464-470. https://doi.org/10.13493/j.issn.1672-7878.2026.05-008
    Objective: To analyze the effect of clinical pharmacist-led individualized pharmaceutical care on vancomycin trough concentrations and medication safety in ICU patients, so as to provide a reference for enhancing rational and safe vancomycin administration. Methods: Patients admitted to the ICU of Wujin Hospital Affiliated to Jiangsu University who received vancomycin therapeutic drug monitoring (TDM) from January 2022 to December 2024 were selected as research subjects. All subjects were divided into three stages: the pre-intervention period (2022), the first year after pharmaceutical intervention (2023), and the second year after intervention (2024). The changes in the distribution of first monitored trough concentrations, target attainment rate, supratherapeutic rate, and incidence of acute kidney injury (AKI) of vancomycin were compared. Results: A total of 162 patients were included, including 51 cases before intervention, 49 cases in the first post-intervention year, and 62 cases in the second post-intervention year. The median trough concentration was higher than 20 mg/L before intervention, decreased in the first post-intervention year, with a statistically significant difference in the second year compared with the trough concentration before intervention (P<0.05). Subgroup analysis was performed according to whether patients received continuous renal replacement therapy (CRRT). In the non-CRRT group, the trough concentration decreased continuously after intervention, with a statistically significant difference in the second year compared with the trough concentration before intervention (P<0.05). In the CRRT group, the trough concentration did not decrease obviously in the first year after intervention, but reduced significantly in the second year, with a statistically significant difference compared with the trough concentration before intervention (P<0.05). The overall initial target attainment rate was 31.37% before intervention, the overall target attainment rate increased to 40.81% in the first post-intervention year with no statistically significant difference compared with that before intervention (P<0.05), and it increased to 50.00% in the second year with a statistically significant difference compared with that before intervention (P<0.05). The rate of supratherapeutic trough concentrations was 50.99% before intervention, decreased to 34.70% in the first post-intervention year and continued to decline in the second year, with no statistically significant difference compared with that before intervention (P>0.05). Although the incidence of vancomycin-associated AKI in the non-CRRT group showed a downward trend after intervention, no statistically significant difference was observed in the incidence of AKI before and after intervention (P>0.05). Conclusion: Clinical pharmacist-led individualized pharmaceutical care for vancomycin can improve the initial trough concentration attainment rate, reduce supratherapeutic concentrations, and show a trend toward a decreased risk of AKI in critically ill patients.
  • LI Rui-hua, LU Huan-jun
    KANGGANRAN YAOXUE. 2026, 23(5): 449-452. https://doi.org/10.13493/j.issn.1672-7878.2026.05-004
    Objective: To analyze the adverse drug reaction identification process and underlying causes in a patient with drug-induced liver injury (DILI) caused by Xinyuan Capsules and traditional Chinese medicine (TCM) decoction, so as to provide a reference for safe and rational clinical medication. Methodsand Results: A 29-year-old female patient with poorly controlled hyperthyroidism took modified TCM decoction (Shengmai Yin and Xiaoyao San) for qi-tonifying, yin-nourishing, liver-soothing and spleen-strengthening effects at an external hospital, and concurrently received Xinyuan Capsules for arrhythmia control. After continuous medication for approximately 3 weeks, she was admitted due to "epigastric pain and distension with dark urine for 5 days". Markedly abnormal liver function was detected on admission. Based on clinical manifestations and laboratory findings, Xinyuan Capsules and TCM decoction were immediately discontinued. The patient was treated with magnesium isoglycyrrhizinate for anti-inflammatory and hepatoprotective effects, glutathione for antioxidation, omeprazole for acid suppression and gastric protection, and intermittent metoclopramide for antiemesis. On day 5 of admission, although epigastric pain was relieved, persistent dark urine, pruritic limb rashes and scleral icterus were observed. The glutamyl transpeptidase level continued to rise and the bilirubin level failed to decrease obviously. Ursodeoxycholic acid was added for jaundice, and topical Fule Cream was given for relief of pruritus. After treatment, the patient's symptoms were substantially improved with resolved epigastric pain and normalized urine color. Relevant indicators on reexamination approached normal ranges, and the patient was discharged. Conclusion: Multiple ingredients, including processed Polygoni Multiflori Radix in Xinyuan Capsules, as well as wine-processed Scutellariae Radix, vinegar-processed Schisandrae Chinensis Fructus, Moutan Cortex and Uncariae Ramulus cum Uncis in TCM decoction, possess potential hepatotoxicity. The combined administration of multiple hepatotoxic herbs and off-label dosing are the major causes of DILI in this case. Clinicians and pharmacists should attach importance to the liver injury risks of Chinese herbal medicines, strengthen medication monitoring and rational drug use education.
  • KANGGANRAN YAOXUE. 2026, 23(4): 384-391. https://doi.org/10.13493/j.issn.1672-7878.2026.04-010
    目的:系统评价复方制剂奈妥匹坦帕洛诺司琼(netupitant/palonosetron,NEPA)预防化疗所致恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)的有效性、安全性和经济性,为医疗机构药品遴选、临床路径优化与合理用药决策提供循证依据。方法:检索 PubMed、Embase、Cochrane Library、中国知网、万方等数据库,检索时限为建库至 2026 年 3 月 29 日;纳入系统评价/meta 分析和经济学研究等资料,对 NEPA 进行快速卫生技术评估。结果:共纳入 12 篇系统评价/meta 分析、12 篇药物经济学研究、2 篇卫生技术评估报告;有效性方面,NEPA 整体期疗效优势显著,优于多种神经激肽 1 受体拮抗剂,急性期疗效相对欠佳,劣于福沙匹坦、阿瑞匹坦等,延迟期疗效稳定,优于阿瑞匹坦;安全性方面,NEPA 的药物不良反应发生率与其他以神经激肽 1 受体拮抗剂为基础的三联方案差异无统计学意义;经济性方面,NEPA 方案具备明显优势。结论:NEPA 在预防 CINV 方面具有良好的综合价值,尤其在延迟期疗效与经济性方面具有一定优势,可作为高致吐性化疗患者止吐方案的重要选择。
  • KANGGANRAN YAOXUE. 2026, 23(5): 487-490. https://doi.org/10.13493/j.issn.1672-7878.2026.05-012
    目的:分析某基层中医院门急诊抗菌药物处方的合理用药情况,为促进基层医疗机构抗菌药物规范使用提供参考。方法:通过医院信息系统,随机抽取 2024 年 9 月—2025 年 8 月习水县中医医院门急诊抗菌药物处方作为研究对象,每月抽取 30 张,共计 360 张;依据《医院处方点评管理规范》、《抗菌药物临床应用指导原则》、《国家抗微生物治疗指南》和药品说明书等资料,对抗菌药物处方进行合理用药点评,分析不合理处方的分布情况。结果:360 张门急诊抗菌药物处方中,合理处方 236 张,处方合理率为 65.56%;不合理处方 124 张,处方不合理率为 34.44%;124 张不合理处方中,问题类型主要为品种选择不当(56 张,占 45.16%)与无明确用药指征(42 张,占 33.87%);不合理处方主要分布于急诊科(35 张,占 28.23%)、儿科(33 张,占 26.61%)与脾胃肝病科(22 张,占 17.74%);不合理处方涉及的抗菌药物种类主要为头孢菌素类药物(54 张,占 41.86%)、青霉素类药物(40 张,占 31.01%)与硝基咪唑类药物(20 张,占 15.50%);不合理处方共涉及 16 种抗菌药物,频次排名前 3 位的品种依次为阿莫西林-克拉维酸钾片、头孢克肟颗粒、头孢克肟胶囊。结论:该基层中医院门急诊抗菌药物使用存在较严重的不合理情况,以品种选择不当和无明确用药指征最为突出;临床药师需进一步强化实时用药干预,持续推进抗菌药物专项处方点评,并针对高频不合理问题开展精准化合理用药培训,从而促进抗菌药物合理使用。
  • KANGGANRAN YAOXUE. 2026, 23(4): 353-357. https://doi.org/10.13493/j.issn.1672-7878.2026.04-006
    目的:分析县域医疗机构国家集中带量采购(以下简称“集采”)药品相关药物不良反应(adverse drug reactions,ADRs)的发生特点与规律,为临床安全用药提供参考。方法:选取 2023 年 7 月 1 日—2025 年 7 月 1 日正安县人民医院和正安县中医院上报至国家药品不良反应监测平台的 233 例集采药品相关 ADRs 报告作为研究资料,收集报告所涉患者性别、年龄、给药途径、ADRs 发生时间、药物类别、累及器官(或系统)与转归等信息进行分析。结果:233 例集采药品相关 ADRs 中,所涉女性患者多于男性患者(148 例 vs 85 例);患者年龄以<15 岁最多(52 例,占 22.32%),其次为 45~<60 岁(49 例,占 21.03%)和 60~<75 岁(38 例,占 16.31%);报告类型主要为“一般”(176 例,占 75.54%),其次为“新的一般”(36 例,占 15.43%);给药途径以静脉给药为主(153 例,占 65.67%),口服给药 73 例(占 31.33%);ADRs 发生时间主要在用药后≤1 h(132 例,占 56.65%);ADRs 例数居前 5 位的药物类别为抗感染药物(112 例,占 48.07%)、妇产科用药(28 例,占 12.02%)、呼吸系统用药(24 例,占 10.30%)、心血管系统用药(24 例,占 10.30%)和解热镇痛抗炎药(13 例,占 5.58%);ADRs 主要累及器官(或系统)为皮肤和皮下组织(121 例次),其次为胃肠系统(78 例次)、神经系统(33 例次);转归方面,经停药、减量和对症治疗后,痊愈 48 例(占 20.60%),好转 178 例(占 76.39%),未好转 3 例(占 1.29%),不详 4 例(占 1.72%),无死亡病例。结论:集采药品相关 ADRs 在儿童、老年和妇产科用药人群中的报告数较高,静脉给药是主要风险途径,抗感染药物报告最多;应加强对特殊人群的用药监测,规范静脉给药指征,完善 ADRs 风险预警机制,保障临床用药安全。
  • GAO Ting, WU Yan, MA Li, XIONG Shi-juan
    KANGGANRAN YAOXUE. 2026, 23(5): 444-448. https://doi.org/10.13493/j.issn.1672-7878.2026.05-003
    Objective: To analyze the diagnosis and treatment course of a patient with visceral leishmaniasis (kala-azar) complicated by hemophagocytic syndrome presenting with fever, pancytopenia and splenomegaly, and to explore anti-infective treatment strategies and key points of pharmaceutical care when first-line agents are unavailable, so as to provide a reference for clinical diagnosis and treatment of this disease. Methodsand Results: A 23-year-old male patient was hospitalized due to persistent hyperpyrexia, splenomegaly and pancytopenia. Bone marrow smears revealed hemophagocytosis and Leishman-Donovan bodies. Metagenomic next-generation sequencing of peripheral blood and bone marrow both detected the Leishmania donovani species complex, establishing the diagnosis of hemophagocytic syndrome secondary to visceral leishmaniasis. Since sodium stibogluconate (pentavalent antimonial) was initially unavailable, liposomal amphotericin B was administered as an alternative anti-leishmanial agent. After pentavalent antimonial was allocated and delivered, the therapeutic regimen was switched immediately. On the next day after the drug switch, the patient's body temperature returned to normal; C-reactive protein and interleukin-6 levels declined, while platelet count recovered steadily. At the end of the treatment course, repeat bone marrow smears showed no Leishman-Donovan bodies, and the patient was discharged with significant clinical improvement. Conclusion: For patients with acute critical visceral leishmaniasis, liposomal amphotericin B acts as an alternative when pentavalent antimonial is unavailable; timely switch to pentavalent antimonial once available can rapidly relieve clinical symptoms. Successful therapeutic outcomes rely on early definite diagnosis, prompt drug conversion, as well as adequate dosage and complete treatment course. Full-cycle pharmaceutical care by clinical pharmacists, with close monitoring of complete blood count, hepatic and renal function, and ECG, is crucial for medication safety and better prognosis.
  • LIU Shou-ling, WANG Zhen, SHEN Yang-chao, LIU Hui
    KANGGANRAN YAOXUE. 2026, 23(4): 358-365. https://doi.org/10.13493/j.issn.1672-7878.2026.04-007
    Inguinal hernia repair is one of the most widely performed surgical procedures worldwide, with an annual volume of over 10 million cases. Although classified as a clean procedure (theoretical risk of surgical site infection (SSI) below 2%), the actual incidence rate of postoperative SSI can reach 4%-8% in clinical practice. Particularly in tension-free hernia repair with mesh implantation, SSI may not only lead to mesh exposure, migration or even surgical removal, but also increase the hernia recurrence rate by 3-5 folds, significantly prolonging hospital stay and raising medical costs. As a key intervention for SSI reduction, the clinical value, agent selection, administration timing and treatment course regarding prophylactic use of antibacterial drugs have long been debated. This article systematically reviews high-quality domestic and international studies (including randomized controlled trials, meta-analyses and guidelines) in the past 10 years, analyzes and summarizes the topic from four dimensions: the evidence base for key controversial issues, the formation logic of clinical consensus, existing problems in practical implementation, and future research directions. It aims to provide a reference for clinicians to develop individualized prophylactic regimens, and offer insights for promoting the rational use of antibacterial drugs and the prevention and control of bacterial resistance.
  • KANGGANRAN YAOXUE. 2026, 23(4): 392-396. https://doi.org/10.13493/j.issn.1672-7878.2026.04-011
    目的:分析热毒宁注射液相关药物不良反应(adverse drug reactions,ADRs)的临床特征,结合药品说明书探讨用药剂量与安全性的关联,为临床安全、精准用药提供参考。方法:选取 2011 年 1 月 1 日—2025 年 12 月 31 日东海县人民医院上报至国家药品不良反应监测中心的 71 例热毒宁注射液 ADRs 报告作为研究资料,收集 ADRs 报告中所涉患者性别和年龄、用药原因、累及器官(或系统)及其临床表现、ADRs 发生时间、热毒宁注射液用量等信息,分析 ADRs 发生特点。结果:71 例热毒宁注射液 ADRs 中,报告类型主要为“一般”(55 例,占 77.46%),其次为“新的一般”(10 例,占 14.08%);ADRs 关联性评价为“可能”的 18 例,“很可能”的 48 例,“肯定”的 5 例;所涉患者男性 40 例(占 56.34%),女性 31 例(占 43.66%);年龄上,<1 岁和1~<2 岁患者较多,分别为 15 例(占 21.13%)和(16 例,占 22.54%);剂量体质量比的中位数和数据离散度随年龄增长呈下降趋势,<3 岁年龄段剂量体质量比中位数最高、离散度最大;ADRs 大部分发生于用药后>5~10 min(32 例,占 45.07%);患者原患疾病分布以呼吸系统疾病为主(57 例,占 80.28%);ADRs 累及器官(或系统)频次最高的为皮肤及其附件(52 例次),其次是消化系统(19 例次);转归情况上,患者好转 46 例(占 64.79%)、痊愈 24 例(占 33.80%)。结论:热毒宁注射液 ADRs 多发生于用药后 30 min内,主要累及皮肤及其附件和消化系统,<3岁患儿高发与说明书剂量信息缺失和用药规范性不足密切相关;建议监管部门、生产企业和医疗机构三方协同,完善说明书特殊人群用药信息,规范临床用药行为,提升用药安全性与精准性。
  • FEI Tian-yu, LU Bing, LIU Dong, LIU Yu, XU Tao, YANG Hui
    KANGGANRAN YAOXUE. 2026, 23(4): 348-352. https://doi.org/10.13493/j.issn.1672-7878.2026.04-005
    Objective: To analyze the pharmaceutical care process of tislelizumab-induced diabetic ketoacidosis (DKA) in a patient with advanced lung adenocarcinoma, and provide a reference for the safe and rational clinical use of immune checkpoint inhibitors (ICIs). Methods and Results: A 61-year-old male patient was admitted due to "over 2 years after surgery for left lung adenocarcinoma and half a day of impaired limb movement". The patient had no prior history of diabetes mellitus and had received 7 cycles of tislelizumab immunotherapy. The admission diagnoses were left lung adenocarcinoma stage IVA (T2N2M1) and chronic intractable pain. On the day of admission, his blood glucose level exceeded 38.86 mmol/L, and urinary ketone bodies tested positive (++). Continuous intravenous insulin infusion at 2 IU/h and fluid replacement were immediately initiated for glycemic control. The patient was subsequently transferred to the ICU due to critical condition, and received symptomatic and supportive treatments including continuous insulin pump therapy, airway management, anti-infective therapy, and acid suppression for gastric mucosal protection. After 3 days of treatment, the patient’s vital signs stabilized, and he was transferred back to the geriatrics department for further treatment, with dynamic blood glucose monitoring and insulin dose adjustment based on glucose levels. After 15 days of treatment, urinary ketone bodies and urinary glucose turned negative, and blood glucose was stably controlled. The patient was discharged with prescribed medications: insulin aspart (8 IU subcutaneously before breakfast, 6 IU subcutaneously before lunch and dinner) and insulin glargine (14 IU subcutaneously at bedtime). He was instructed to continue blood glucose monitoring and insulin dose adjustment after discharge. Conclusion: Vigilance against immune-related adverse reactions is required during ICI therapy. In clinical practice, blood glucose monitoring and management should be strengthened, and DKA should be identified and managed promptly to ensure medication safety of patients.
  • LI Mei-ling
    KANGGANRAN YAOXUE. 2026, 23(5): 456-459. https://doi.org/10.13493/j.issn.1672-7878.2026.05-006
    Objective: To analyze the identification process and occurrence mechanism of severe thrombocytopenia induced by tirofiban in a patient with acute stroke, so as to provide a reference for safe clinical medication. Methodsand Results: A 75-year-old male patient was admitted for acute cerebral infarction with a baseline platelet count of 162×109/L. After alteplase thrombolysis, tirofiban was administered via intravenous pump for antiplatelet aggregation on the next day. Approximately 1 hour after administration, the patient developed sudden chills, high fever and scattered ecchymoses on the left upper extremity. Tirofiban was discontinued immediately, and emergency testing showed that the platelet count dropped sharply to 18×109/L. Symptomatic treatment was given, including diazepam, promethazine and paracetamol. Two units of ABO-identical leukoreduced apheresis platelets were transfused on day 2 after drug discontinuation. One day after transfusion, the platelet count recovered to 233×109/L, and the skin ecchymoses were significantly improved. Conclusion: Tirofiban is a commonly used antiplatelet agent in clinical practice, but it can induce acute severe thrombocytopenia shortly after administration. Close monitoring of platelet count is required during clinical use, especially within the initial hours of treatment. For high-risk elderly patients with multiple underlying diseases, intensified monitoring frequency is essential to ensure medication safety.